Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers

Next Previous
Trial Profile

Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Faldaprevir (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B; HIV infections
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 04 Mar 2013 Results have been presented at the 2013 CROI: Conference on Retroviruses and Opportunistic Infections according to a Boehringer Ingelheim media release.
  • 28 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 01 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top